Latest news with #PHI
Geeky Gadgets
6 days ago
- Business
- Geeky Gadgets
Choose Secure Data Erasure Over Factory Reset for Mac
Apple Silicon or Intel-based Macs have an option to be reset to factory mode. Once the Mac device is reset, all the applications and saved personal data are formatted, and the device is restored to factory settings. This hard reset frees up storage space, deleting stored data and thereby increasing its processing speed. Several areas on the disk store data such as user credentials, built-in app data, backup information, etc., that are inaccessible to the user, operating system, BIOS, or UEFI. Existing in different forms, Host Protected Area (HPA), Disk Configuration Overlay (DCO), or Accessible Max Address (AMA), these hidden disk areas mainly contain disk utilities for the device to function smoothly. It is of utmost importance that data from these disk zones be erased to prevent data leakage. However, a factory reset is incapable of fulfilling this purpose. The Hidden Risks: Recoverable Data Post Factory Reset A factory reset only removes the pointers to the file system, removing only access to the data and not the data itself. In most cases, the actual contents of the Mac drive still reside on the Mac, which is recoverable using freely available Mac data recovery software or through forensic in-lab services. The data traces left behind after a factory reset can comprise Personally Identifiable Information (PII), Protected Health Information (PHI), credit card information, etc., which, if leaked, can ruin decades of reputation for a business in seconds, and this is just the beginning. Data protection laws and regulations like EU-GDPR, HIPAA, CCPA, GLBA, etc., require businesses to erase personal data collected for processing after the retention period is over, the purpose has been served, or the individual has requested the removal of their data. Data removal has to be permanent beyond recovery from the entire Mac device, including inaccessible disk zones HPA, DCO, and other remapped sectors. Contrary to popular belief, a factory reset does not meet the secure erase requirements such as those needed by NIST 800-88, DoD 5220.22 M, or other regulatory guidelines. On Mac devices with SSDs, data is stored in memory blocks that also have the TRIM command enabled. While TRIM helps in optimizing the performance of SSDs, however, there is no way to ensure that the data has been permanently erased, as the TRIM command can be disabled by individuals, either intentionally or due to system configurations. Further, laws also mandate a proof of data destruction to be maintained by the organization in the form of a report or certificate of destruction. A software-based data erasure tool is highly recommended if the Mac devices are in a functional state and the business intends to reuse them; however, if the device is non-functional and cannot be repaired, then the device must be destroyed using physical destruction methods. The Real World Impact: When Factory Reset Fails Consider an organization that has no policies or mechanisms in place for data destruction. For reusing, repurposing, reselling, or donating their end-of-life devices, including Mac devices, the organization performs a factory reset on all the functional devices. These reset devices are either handed over to their new owners or discarded. Since the business-critical information still remains on these devices, the threat to data privacy lingers continually. The sensitive information can be recovered from all these devices using forensic tools or data recovery software, which can then be misused or can result in a data breach episode. The 2016 Morgan Stanley data breach case is one such example where confidential data such as social security numbers, passports, and credit card information, was recovered from decommissioned IT assets. These IT assets were not only not properly erased but also were resold to a third party without sanitization verification. This unauthorized access to personal data brought the organization penalties close to USD 100 million imposed by authorities, including the Office of the Comptroller of the Currency (OCC) and Securities and Exchange Commission (SEC), over a span of more than 5 years. One data breach caused Morgan Stanley operational downtime, penalties, and loss of customer trust. The Secure Solution: Software-Based Data Erasure Organizations must devise data destruction policies, including data retention guidelines, to ensure secure erasure is performed periodically without any scope for gaps in the process. The policies should also include guidelines on how data of varying sensitivity should be securely erased from different Mac devices and what tool should be used to perform secure data erasure. For example, the Mac devices containing data related to intellectual property or financial information that is critical must be sanitized using a certified data erasure tool like BitRaser before Mac devices are reallocated or refurbished. A software-based data erasure tool applies international data erasure algorithms like NIST 800-88 Clear, NIST 800-88 Purge, and DoD 5220.22 M (3 pass). It permanently erases data from all devices, including Mac's with erasure from inaccessible hidden disk areas. It also generates immutable erasure reports and a certificate of data destruction, which assist in complying with the governing data protection laws and regulations. Resetting Isn't Enough, Erasure is Essential Organizations have always been proactive in adapting to modern-day technology to gain more profits, gain a competitive edge, and establish their brand as progressive. However, many lag in assimilating this strategy when it comes to policy implementation in terms of data destruction. The risk of a data breach creeps over every business today, whether it is a startup or an enterprise. According to IBM's Cost of a Data Breach Report 2024, an average data breach costs USD 4.88 million. This cost is 10% higher than that mentioned in the IBM 2023 report. Clearly, there is a dire need for organizations to prevent data breaches by including secure data erasure as one of their cybersecurity strategies. To prevent this risk from turning into a tragic event, businesses must leverage data erasure programs to destroy data on their Mac devices, comply with the requirements of data protection laws, and build trust with their customers. Compliance is no longer optional, and a factory reset is not compliant. Filed Under: Apple, Guides, Laptops Latest Geeky Gadgets Deals Disclosure: Some of our articles include affiliate links. If you buy something through one of these links, Geeky Gadgets may earn an affiliate commission. Learn about our Disclosure Policy.
Yahoo
21-05-2025
- Business
- Yahoo
Prostate Cancer Diagnostics Solution Market Trends, Challenges and Future Outlook
Prostate Cancer Diagnostics Solution Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Global Prostate Cancer Diagnostics Solution Market The global prostate cancer diagnostics solution market is undergoing a significant transformation, propelled by technological advances, improved patient awareness, and increased healthcare spending. In 2024, the market size is valued at approximately USD 4.18 billion, and it is forecast to reach USD 10.84 billion by 2034, reflecting a strong CAGR of 10%. This growth is primarily fueled by the increasing incidence of prostate cancer globally, driven in part by an aging population, better screening coverage, and enhancements in molecular and imaging-based diagnostics. Get a Sample PDF Brochure: Prostate cancer remains one of the most prevalent malignancies among men, especially in North America and Europe. While early detection significantly improves prognosis, traditional diagnostic methods such as PSA screening and manual biopsies face criticism for low specificity and overdiagnosis. In response, the market is witnessing a shift toward precision diagnostics using biomarkers, genetic assays, and advanced imaging systems. Market Growth Drivers The market is influenced by several factors. First, the growing awareness around early screening programs, especially in developed nations, has led to a significant uptick in test volumes. Public health campaigns and evolving guidelines from organizations like the American Urological Association (AUA) and European Association of Urology (EAU) encourage age-appropriate prostate screening. Secondly, technology has improved both the sensitivity and specificity of diagnostic tools. Multiparametric MRI, PSMA-based imaging, liquid biopsy, and AI-assisted pathology have reduced false positives and enabled targeted biopsies. Healthcare providers are increasingly integrating prostate-specific biomarkers such as PCA3, 4Kscore, SelectMDx, and PHI (Prostate Health Index) into diagnostic workflows. Molecular diagnostics and genomic profiling are also gaining traction for risk stratification and treatment planning. For instance, gene expression panels help differentiate between indolent and aggressive tumors, enabling clinicians to tailor active surveillance or treatment strategies. Emerging markets in Asia-Pacific, Latin America, and the Middle East are also contributing to market expansion. Improved healthcare infrastructure, greater access to insurance, and the establishment of private diagnostic centers have expanded access to prostate cancer testing beyond urban centers. Governments in countries like China, India, and Brazil are prioritizing cancer screening under national health plans, further accelerating adoption. Challenges and Constraints Despite promising growth, the prostate cancer diagnostics market faces several challenges. Overdiagnosis and overtreatment remain concerns, particularly in cases where low-risk tumors are detected. Invasive diagnostic procedures, such as transrectal ultrasound (TRUS)-guided biopsies, are associated with discomfort, infection risk, and high costs. Moreover, the accessibility of advanced imaging and molecular testing remains limited in low-income regions. Regulatory barriers also affect product adoption. Diagnostic test developers must navigate complex approval processes, such as FDA clearance and CE marking, which can delay commercialization. Furthermore, reimbursement coverage for newer tests varies significantly across markets, limiting patient access to cutting-edge solutions in some areas. Browse full Report - Market Segmentation By Product Type Imaging continues to dominate the market owing to its role in tumor localization and staging. This includes multiparametric MRI and PSMA-PET, which are essential for visualizing high-risk tumors. Biomarkers, on the other hand, are rapidly gaining popularity, especially with non-invasive urine and blood-based tests that offer high specificity. Biopsy devices remain essential, particularly for confirmatory diagnosis. The prostate cancer diagnostics market is segmented into imaging, biomarkers, and biopsy devices. Product Type 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Imaging 40% 4.34 9.5% Biomarkers 35% 3.79 10.2% Biopsy Devices 25% 2.71 10.8% By Application Screening forms the foundation of prostate cancer prevention strategies, accounting for the largest market share. Diagnosis is growing steadily with the adoption of precision-guided biopsy methods. Monitoring applications are increasingly important in active surveillance models and recurrence tracking. Applications include screening, diagnosis, and monitoring. Application 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Screening 45% 4.88 9.8% Diagnosis 35% 3.79 10.1% Monitoring 20% 2.17 10.5% By End User Hospitals are the largest end users due to their integrated imaging, pathology, and urology departments. Diagnostic laboratories follow closely, with specialized labs offering advanced biomarker panels and gene sequencing. Research institutes contribute to market development through clinical trials and new test validation. End users encompass hospitals, diagnostic laboratories, and research institutes. End User 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Hospitals 50% 5.42 9.9% Diagnostic Labs 35% 3.79 10.2% Research Institutes 15% 1.63 10.4% By Technology Immunohistochemistry techniques remain widely used due to their cost-effectiveness and accessibility. Molecular diagnostics are growing rapidly, especially with NGS and PCR-based tests enabling more accurate diagnosis. Imaging techniques continue to evolve, with AI-assisted MRI and PSMA scans reshaping early detection. Technologies include immunohistochemistry, molecular diagnostics, and imaging techniques. Technology 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Immunohistochemistry 40% 4.34 9.5% Molecular Diagnostics 35% 3.79 10.2% Imaging Techniques 25% 2.71 10.8% By Distribution Channel Direct sales dominate the market as most products are sold directly to hospitals and diagnostic centers. Distributors play a key role in reaching secondary markets and mid-sized labs. Online sales are growing quickly, particularly for biomarker kits and reagent supplies, driven by digital procurement platforms. Distribution channels comprise direct sales, distributors, and online sales. Distribution Channel 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Direct Sales 50% 5.42 9.9% Distributors 30% 3.25 10.3% Online Sales 20% 2.17 10.5% Recent Developments EDX Medical Group has developed an AI-driven prostate cancer supertest that measures over 100 biomarkers using blood and urine samples, achieving 96% accuracy. This test is expected to revolutionize early detection and personalized treatment plans . Telix Pharmaceuticals received FDA approval for Gozellix, a prostate cancer screening agent designed for PET scanning of PSMA-positive lesions, offering a longer shelf life and enhanced clinical utility . Key Players Abbott Laboratories Siemens Healthineers Roche Diagnostics Hologic, Inc. Myriad Genetics, Inc. OPKO Health, Inc. Genomic Health (Exact Sciences Corporation) MDxHealth Beckman Coulter, Inc. Thermo Fisher Scientific Inc. Market Outlook In the next decade, the prostate cancer diagnostics market is expected to continue evolving toward non-invasive, high-accuracy, and personalized testing paradigms. AI integration will play a pivotal role in radiology and pathology, helping clinicians interpret results faster and more accurately. The convergence of imaging, molecular diagnostics, and clinical decision support tools is paving the way for comprehensive, data-driven diagnostic ecosystems. Industry players are likely to invest in integrated diagnostic platforms, point-of-care testing innovations, and strategic collaborations with research institutions. Startups and biotech firms are actively exploring liquid biopsy techniques and next-generation sequencing (NGS) for early detection and risk profiling. At the same time, healthcare systems are adopting risk-based screening models to optimize resources and minimize overtreatment. With increased emphasis on preventive care and patient-centered medicine, prostate cancer diagnostics are poised to become more accessible, reliable, and cost-effective worldwide. Stakeholders that prioritize innovation, regulatory agility, and affordability are expected to capture significant market share in this rapidly expanding field. This report is also available in the following languages : Japanese (前立腺がん診断ソリューション市場), Korean (전립선암 진단 솔루션 시장), Chinese (前列腺癌诊断解决方案市场), French (Marché des solutions de diagnostic du cancer de la prostate), German (Markt für Prostatakrebsdiagnostiklösungen), and Italian (Mercato delle soluzioni diagnostiche per il cancro alla prostata), etc. Download Full PDF Sample Copy of Market Report @ Related reports – Handheld Acoustic Camera Market The global handheld acoustic camera market is valued at approximately $120 million, reflecting a growing interest in innovative sound visualization technologies. The market is projected to reach around $250 million by 2034, driven by advancements in sensor technology, increased demand from various sectors, and rising awareness of sound management in industrial applications. Fully Automatic Autoclave Market The global fully automatic autoclave market is valued at approximately $1.2 billion in 2024, with a projected growth trajectory that anticipates a market value of around $2.0 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Veterinary Diagnostic Kits Market The global veterinary diagnostic kits market is valued at approximately $3.2 billion in 2024 and is projected to reach around $5.4 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period from 2025 to 2034. Poultry Disease Diagnostic Kit Market The global poultry disease diagnostic kit market is valued at approximately $920 million in 2024, reflecting a robust growth trajectory driven by increasing poultry production and a rising focus on animal health. By 2034, the market is projected to reach around $1.8 billion, representing significant expansion fueled by advancements in diagnostic technologies and increased awareness of poultry disease management. GIST Mutation Detection Kit Market The global market for GIST (Gastrointestinal Stromal Tumors) mutation detection kits is valued at approximately $405 million. This market is projected to grow to around $700 million by 2034, reflecting an estimated compound annual growth rate (CAGR) of 6.0%. HPV Genotyping Detection Kit Market The global HPV genotyping detection kit market is poised for significant growth, with an estimated market value of approximately USD 2.5 billion in 2024. This market is projected to expand to around USD 5.3 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8% during the forecast period of 2025–2034. Virus DNA Extraction Kit Market The global market for virus DNA extraction kits is valued at approximately $1.2 billion in 2024, driven by increasing research activities in genomics and molecular diagnostics. The market is projected to reach about $2.3 billion by 2034, reflecting a robust growth trajectory. This translates to a Compound Annual Growth Rate (CAGR) of around 7.1% during the forecast period from 2025 to 2034. SARS-CoV-2 IgM and IgG Antibody Test Kit(Colloidal Gold Method) Market The global market for SARS-CoV-2 IgM and IgG antibody test kits, particularly those utilizing the colloidal gold method, is valued at approximately $1.2 billion. This market is projected to expand significantly, achieving a value of around $2.8 billion by 2034, driven by increasing demand for rapid and accurate COVID-19 testing solutions. The Compound Annual Growth Rate (CAGR) for this forecast period is estimated at 8.5%. SARS-CoV-2 Antigen Test Kit Market The global market for SARS-CoV-2 antigen test kits is projected to reach approximately $4.5 billion in 2024, fueled by continued demand for rapid testing solutions amidst ongoing public health considerations. Over the forecast period from 2025 to 2034, the market is expected to expand significantly, with a projected market value of around $7 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 5.5%, driven by enhanced manufacturing capabilities, technological advancements, and the growing emphasis on home testing solutions. Plasma Autoclave Market The global plasma autoclave market is valued at approximately $500 million in 2024, with expectations to reach around $900 million by 2034. This growth trajectory reflects a robust compound annual growth rate (CAGR) of approximately 6% from 2025 to 2034. Alkaline Bicarbonate Hemodialysis Concentrate Market The global alkaline bicarbonate hemodialysis concentrate market is valued at approximately $2.8 billion. The market is poised for significant growth, with a projected value of around $4.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.0% during the forecast period of 2025–2034. Dental Coloring Liquid Market The global dental coloring liquid market is valued at approximately $540 million in 2024, with an anticipated growth trajectory that will see it reach around $1.1 billion by 2034. The expected Compound Annual Growth Rate (CAGR) during the forecast period, from 2025 to 2034, is projected to be about 7.3%. Dental Polishing Paste Market The global dental polishing paste market is projected to reach approximately $335 million in 2024, with a steady growth trajectory anticipated over the next decade. By 2034, the market value is expected to expand to around $520 million, reflecting a compound annual growth rate (CAGR) of approximately 4.4% during the forecast period of 2025–2034. Dental Acid Etching Agent Market The global dental acid etching agent market is projected to reach a value of approximately $350 million in 2024, driven by the rising demand for cosmetic dentistry and advancements in dental materials. During the forecast period from 2025 to 2034, the market is anticipated to grow at a CAGR of 6.5%, driven by increasing dental care awareness, technological innovations, and the growing prevalence of dental disorders. Root Canal Lubricant Market The global root canal lubricant market is valued at approximately $180 million in 2024, with projections indicating a robust growth trajectory, reaching an estimated $300 million by 2034. This reflects a Compound Annual Growth Rate (CAGR) of around 5.1% over the forecast period from 2025 to 2034. Laryngeal and Tracheal Stents Market The global laryngeal and tracheal stents market is valued at approximately $450 million. Projections indicate significant growth, with an estimated market value of $1.1 billion by 2034, signaling a robust expansion driven by advancements in medical technology and increasing prevalence of respiratory conditions. Pharmaceutical Grade Medium Chain Triglyceride (MCT) Market The global pharmaceutical-grade medium chain triglyceride (MCT) market is valued at approximately $550 million, fueled by rising health awareness and the increasing use of MCT in dietary supplements and clinical nutrition. The market is projected to grow significantly, reaching an estimated value of $1.2 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of 8.1% over the forecast period from 2025 to 2034. Hydroxyethyl Starch API Market The global Hydroxyethyl Starch (HES) API market is estimated at approximately USD 675 million in 2024, with a projected value reaching around USD 1.1 billion by 2034. This growth reflects a robust compound annual growth rate (CAGR) of about 5.1% for the period from 2025 to 2034. Pet Wellness Exams Market The global pet wellness exams market is expected to reach a value of approximately $3.5 billion in 2024, driven by increasing pet ownership and a growing emphasis on preventive healthcare. The projected market value is estimated to rise to around $5.8 billion by 2034, reflecting a robust demand for wellness services in the pet care sector. Enteric Pathogen Test Kits Market The global market for enteric pathogen test kits is valued at approximately $1.2 billion in 2024, driven by heightened consumer awareness regarding food safety and stringent regulatory frameworks. The market is projected to reach around $2.3 billion by 2034, reflecting robust growth opportunities in both emerging and established markets. CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
Prostate Cancer Diagnostics Solution Market Trends, Challenges and Future Outlook
Prostate Cancer Diagnostics Solution Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Global Prostate Cancer Diagnostics Solution Market The global prostate cancer diagnostics solution market is undergoing a significant transformation, propelled by technological advances, improved patient awareness, and increased healthcare spending. In 2024, the market size is valued at approximately USD 4.18 billion, and it is forecast to reach USD 10.84 billion by 2034, reflecting a strong CAGR of 10%. This growth is primarily fueled by the increasing incidence of prostate cancer globally, driven in part by an aging population, better screening coverage, and enhancements in molecular and imaging-based diagnostics. Get a Sample PDF Brochure: Prostate cancer remains one of the most prevalent malignancies among men, especially in North America and Europe. While early detection significantly improves prognosis, traditional diagnostic methods such as PSA screening and manual biopsies face criticism for low specificity and overdiagnosis. In response, the market is witnessing a shift toward precision diagnostics using biomarkers, genetic assays, and advanced imaging systems. Market Growth Drivers The market is influenced by several factors. First, the growing awareness around early screening programs, especially in developed nations, has led to a significant uptick in test volumes. Public health campaigns and evolving guidelines from organizations like the American Urological Association (AUA) and European Association of Urology (EAU) encourage age-appropriate prostate screening. Secondly, technology has improved both the sensitivity and specificity of diagnostic tools. Multiparametric MRI, PSMA-based imaging, liquid biopsy, and AI-assisted pathology have reduced false positives and enabled targeted biopsies. Healthcare providers are increasingly integrating prostate-specific biomarkers such as PCA3, 4Kscore, SelectMDx, and PHI (Prostate Health Index) into diagnostic workflows. Molecular diagnostics and genomic profiling are also gaining traction for risk stratification and treatment planning. For instance, gene expression panels help differentiate between indolent and aggressive tumors, enabling clinicians to tailor active surveillance or treatment strategies. Emerging markets in Asia-Pacific, Latin America, and the Middle East are also contributing to market expansion. Improved healthcare infrastructure, greater access to insurance, and the establishment of private diagnostic centers have expanded access to prostate cancer testing beyond urban centers. Governments in countries like China, India, and Brazil are prioritizing cancer screening under national health plans, further accelerating adoption. Challenges and Constraints Despite promising growth, the prostate cancer diagnostics market faces several challenges. Overdiagnosis and overtreatment remain concerns, particularly in cases where low-risk tumors are detected. Invasive diagnostic procedures, such as transrectal ultrasound (TRUS)-guided biopsies, are associated with discomfort, infection risk, and high costs. Moreover, the accessibility of advanced imaging and molecular testing remains limited in low-income regions. Regulatory barriers also affect product adoption. Diagnostic test developers must navigate complex approval processes, such as FDA clearance and CE marking, which can delay commercialization. Furthermore, reimbursement coverage for newer tests varies significantly across markets, limiting patient access to cutting-edge solutions in some areas. Browse full Report - Market Segmentation By Product Type Imaging continues to dominate the market owing to its role in tumor localization and staging. This includes multiparametric MRI and PSMA-PET, which are essential for visualizing high-risk tumors. Biomarkers, on the other hand, are rapidly gaining popularity, especially with non-invasive urine and blood-based tests that offer high specificity. Biopsy devices remain essential, particularly for confirmatory diagnosis. The prostate cancer diagnostics market is segmented into imaging, biomarkers, and biopsy devices. Product Type 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Imaging 40% 4.34 9.5% Biomarkers 35% 3.79 10.2% Biopsy Devices 25% 2.71 10.8% By Application Screening forms the foundation of prostate cancer prevention strategies, accounting for the largest market share. Diagnosis is growing steadily with the adoption of precision-guided biopsy methods. Monitoring applications are increasingly important in active surveillance models and recurrence tracking. Applications include screening, diagnosis, and monitoring. Application 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Screening 45% 4.88 9.8% Diagnosis 35% 3.79 10.1% Monitoring 20% 2.17 10.5% By End User Hospitals are the largest end users due to their integrated imaging, pathology, and urology departments. Diagnostic laboratories follow closely, with specialized labs offering advanced biomarker panels and gene sequencing. Research institutes contribute to market development through clinical trials and new test validation. End users encompass hospitals, diagnostic laboratories, and research institutes. End User 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Hospitals 50% 5.42 9.9% Diagnostic Labs 35% 3.79 10.2% Research Institutes 15% 1.63 10.4% By Technology Immunohistochemistry techniques remain widely used due to their cost-effectiveness and accessibility. Molecular diagnostics are growing rapidly, especially with NGS and PCR-based tests enabling more accurate diagnosis. Imaging techniques continue to evolve, with AI-assisted MRI and PSMA scans reshaping early detection. Technologies include immunohistochemistry, molecular diagnostics, and imaging techniques. Technology 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Immunohistochemistry 40% 4.34 9.5% Molecular Diagnostics 35% 3.79 10.2% Imaging Techniques 25% 2.71 10.8% By Distribution Channel Direct sales dominate the market as most products are sold directly to hospitals and diagnostic centers. Distributors play a key role in reaching secondary markets and mid-sized labs. Online sales are growing quickly, particularly for biomarker kits and reagent supplies, driven by digital procurement platforms. Distribution channels comprise direct sales, distributors, and online sales. Distribution Channel 2024 Market Share (%) 2034 Market Value (USD Billion) CAGR (2025–2034) Direct Sales 50% 5.42 9.9% Distributors 30% 3.25 10.3% Online Sales 20% 2.17 10.5% Recent Developments EDX Medical Group has developed an AI-driven prostate cancer supertest that measures over 100 biomarkers using blood and urine samples, achieving 96% accuracy. This test is expected to revolutionize early detection and personalized treatment plans . Telix Pharmaceuticals received FDA approval for Gozellix, a prostate cancer screening agent designed for PET scanning of PSMA-positive lesions, offering a longer shelf life and enhanced clinical utility . Key Players Abbott Laboratories Siemens Healthineers Roche Diagnostics Hologic, Inc. Myriad Genetics, Inc. OPKO Health, Inc. Genomic Health (Exact Sciences Corporation) MDxHealth Beckman Coulter, Inc. Thermo Fisher Scientific Inc. Market Outlook In the next decade, the prostate cancer diagnostics market is expected to continue evolving toward non-invasive, high-accuracy, and personalized testing paradigms. AI integration will play a pivotal role in radiology and pathology, helping clinicians interpret results faster and more accurately. The convergence of imaging, molecular diagnostics, and clinical decision support tools is paving the way for comprehensive, data-driven diagnostic ecosystems. Industry players are likely to invest in integrated diagnostic platforms, point-of-care testing innovations, and strategic collaborations with research institutions. Startups and biotech firms are actively exploring liquid biopsy techniques and next-generation sequencing (NGS) for early detection and risk profiling. At the same time, healthcare systems are adopting risk-based screening models to optimize resources and minimize overtreatment. With increased emphasis on preventive care and patient-centered medicine, prostate cancer diagnostics are poised to become more accessible, reliable, and cost-effective worldwide. Stakeholders that prioritize innovation, regulatory agility, and affordability are expected to capture significant market share in this rapidly expanding field. This report is also available in the following languages : Japanese (前立腺がん診断ソリューション市場), Korean (전립선암 진단 솔루션 시장), Chinese (前列腺癌诊断解决方案市场), French (Marché des solutions de diagnostic du cancer de la prostate), German (Markt für Prostatakrebsdiagnostiklösungen), and Italian (Mercato delle soluzioni diagnostiche per il cancro alla prostata), etc. Download Full PDF Sample Copy of Market Report @ Related reports – Handheld Acoustic Camera Market The global handheld acoustic camera market is valued at approximately $120 million, reflecting a growing interest in innovative sound visualization technologies. The market is projected to reach around $250 million by 2034, driven by advancements in sensor technology, increased demand from various sectors, and rising awareness of sound management in industrial applications. Fully Automatic Autoclave Market The global fully automatic autoclave market is valued at approximately $1.2 billion in 2024, with a projected growth trajectory that anticipates a market value of around $2.0 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Veterinary Diagnostic Kits Market The global veterinary diagnostic kits market is valued at approximately $3.2 billion in 2024 and is projected to reach around $5.4 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period from 2025 to 2034. Poultry Disease Diagnostic Kit Market The global poultry disease diagnostic kit market is valued at approximately $920 million in 2024, reflecting a robust growth trajectory driven by increasing poultry production and a rising focus on animal health. By 2034, the market is projected to reach around $1.8 billion, representing significant expansion fueled by advancements in diagnostic technologies and increased awareness of poultry disease management. GIST Mutation Detection Kit Market The global market for GIST (Gastrointestinal Stromal Tumors) mutation detection kits is valued at approximately $405 million. This market is projected to grow to around $700 million by 2034, reflecting an estimated compound annual growth rate (CAGR) of 6.0%. HPV Genotyping Detection Kit Market The global HPV genotyping detection kit market is poised for significant growth, with an estimated market value of approximately USD 2.5 billion in 2024. This market is projected to expand to around USD 5.3 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 8% during the forecast period of 2025–2034. Virus DNA Extraction Kit Market The global market for virus DNA extraction kits is valued at approximately $1.2 billion in 2024, driven by increasing research activities in genomics and molecular diagnostics. The market is projected to reach about $2.3 billion by 2034, reflecting a robust growth trajectory. This translates to a Compound Annual Growth Rate (CAGR) of around 7.1% during the forecast period from 2025 to 2034. SARS-CoV-2 IgM and IgG Antibody Test Kit(Colloidal Gold Method) Market The global market for SARS-CoV-2 IgM and IgG antibody test kits, particularly those utilizing the colloidal gold method, is valued at approximately $1.2 billion. This market is projected to expand significantly, achieving a value of around $2.8 billion by 2034, driven by increasing demand for rapid and accurate COVID-19 testing solutions. The Compound Annual Growth Rate (CAGR) for this forecast period is estimated at 8.5%. SARS-CoV-2 Antigen Test Kit Market The global market for SARS-CoV-2 antigen test kits is projected to reach approximately $4.5 billion in 2024, fueled by continued demand for rapid testing solutions amidst ongoing public health considerations. Over the forecast period from 2025 to 2034, the market is expected to expand significantly, with a projected market value of around $7 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 5.5%, driven by enhanced manufacturing capabilities, technological advancements, and the growing emphasis on home testing solutions. Plasma Autoclave Market The global plasma autoclave market is valued at approximately $500 million in 2024, with expectations to reach around $900 million by 2034. This growth trajectory reflects a robust compound annual growth rate (CAGR) of approximately 6% from 2025 to 2034. Alkaline Bicarbonate Hemodialysis Concentrate Market The global alkaline bicarbonate hemodialysis concentrate market is valued at approximately $2.8 billion. The market is poised for significant growth, with a projected value of around $4.5 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.0% during the forecast period of 2025–2034. Dental Coloring Liquid Market The global dental coloring liquid market is valued at approximately $540 million in 2024, with an anticipated growth trajectory that will see it reach around $1.1 billion by 2034. The expected Compound Annual Growth Rate (CAGR) during the forecast period, from 2025 to 2034, is projected to be about 7.3%. Dental Polishing Paste Market The global dental polishing paste market is projected to reach approximately $335 million in 2024, with a steady growth trajectory anticipated over the next decade. By 2034, the market value is expected to expand to around $520 million, reflecting a compound annual growth rate (CAGR) of approximately 4.4% during the forecast period of 2025–2034. Dental Acid Etching Agent Market The global dental acid etching agent market is projected to reach a value of approximately $350 million in 2024, driven by the rising demand for cosmetic dentistry and advancements in dental materials. During the forecast period from 2025 to 2034, the market is anticipated to grow at a CAGR of 6.5%, driven by increasing dental care awareness, technological innovations, and the growing prevalence of dental disorders. Root Canal Lubricant Market The global root canal lubricant market is valued at approximately $180 million in 2024, with projections indicating a robust growth trajectory, reaching an estimated $300 million by 2034. This reflects a Compound Annual Growth Rate (CAGR) of around 5.1% over the forecast period from 2025 to 2034. Laryngeal and Tracheal Stents Market The global laryngeal and tracheal stents market is valued at approximately $450 million. Projections indicate significant growth, with an estimated market value of $1.1 billion by 2034, signaling a robust expansion driven by advancements in medical technology and increasing prevalence of respiratory conditions. Pharmaceutical Grade Medium Chain Triglyceride (MCT) Market The global pharmaceutical-grade medium chain triglyceride (MCT) market is valued at approximately $550 million, fueled by rising health awareness and the increasing use of MCT in dietary supplements and clinical nutrition. The market is projected to grow significantly, reaching an estimated value of $1.2 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of 8.1% over the forecast period from 2025 to 2034. Hydroxyethyl Starch API Market The global Hydroxyethyl Starch (HES) API market is estimated at approximately USD 675 million in 2024, with a projected value reaching around USD 1.1 billion by 2034. This growth reflects a robust compound annual growth rate (CAGR) of about 5.1% for the period from 2025 to 2034. Pet Wellness Exams Market The global pet wellness exams market is expected to reach a value of approximately $3.5 billion in 2024, driven by increasing pet ownership and a growing emphasis on preventive healthcare. The projected market value is estimated to rise to around $5.8 billion by 2034, reflecting a robust demand for wellness services in the pet care sector. Enteric Pathogen Test Kits Market The global market for enteric pathogen test kits is valued at approximately $1.2 billion in 2024, driven by heightened consumer awareness regarding food safety and stringent regulatory frameworks. The market is projected to reach around $2.3 billion by 2034, reflecting robust growth opportunities in both emerging and established markets. CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
16-05-2025
- Business
- Washington Post
PLDT: Q1 Earnings Snapshot
MAKATI, Philippines — MAKATI, Philippines — Philippine Long Distance Telephone Co. (PHI) on Thursday reported profit of $155.7 million in its first quarter. On a per-share basis, the Makati, Philippines-based company said it had net income of 72 cents. Earnings, adjusted for non-recurring gains, were 71 cents per share. The telecommunications company posted revenue of $953.9 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on PHI at
Yahoo
16-05-2025
- Business
- Yahoo
PLDT: Q1 Earnings Snapshot
MAKATI, Philippines (AP) — MAKATI, Philippines (AP) — Philippine Long Distance Telephone Co. (PHI) on Thursday reported profit of $155.7 million in its first quarter. On a per-share basis, the Makati, Philippines-based company said it had net income of 72 cents. Earnings, adjusted for non-recurring gains, were 71 cents per share. The telecommunications company posted revenue of $953.9 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on PHI at
